Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan
- PMID: 18604266
- PMCID: PMC2430535
- DOI: 10.1371/journal.pcbi.1000107
Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan
Abstract
CD4 positive T helper cells control many aspects of specific immunity. These cells are specific for peptides derived from protein antigens and presented by molecules of the extremely polymorphic major histocompatibility complex (MHC) class II system. The identification of peptides that bind to MHC class II molecules is therefore of pivotal importance for rational discovery of immune epitopes. HLA-DR is a prominent example of a human MHC class II. Here, we present a method, NetMHCIIpan, that allows for pan-specific predictions of peptide binding to any HLA-DR molecule of known sequence. The method is derived from a large compilation of quantitative HLA-DR binding events covering 14 of the more than 500 known HLA-DR alleles. Taking both peptide and HLA sequence information into account, the method can generalize and predict peptide binding also for HLA-DR molecules where experimental data is absent. Validation of the method includes identification of endogenously derived HLA class II ligands, cross-validation, leave-one-molecule-out, and binding motif identification for hitherto uncharacterized HLA-DR molecules. The validation shows that the method can successfully predict binding for HLA-DR molecules-even in the absence of specific data for the particular molecule in question. Moreover, when compared to TEPITOPE, currently the only other publicly available prediction method aiming at providing broad HLA-DR allelic coverage, NetMHCIIpan performs equivalently for alleles included in the training of TEPITOPE while outperforming TEPITOPE on novel alleles. We propose that the method can be used to identify those hitherto uncharacterized alleles, which should be addressed experimentally in future updates of the method to cover the polymorphism of HLA-DR most efficiently. We thus conclude that the presented method meets the challenge of keeping up with the MHC polymorphism discovery rate and that it can be used to sample the MHC "space," enabling a highly efficient iterative process for improving MHC class II binding predictions.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
TEPITOPEpan: extending TEPITOPE for peptide binding prediction covering over 700 HLA-DR molecules.PLoS One. 2012;7(2):e30483. doi: 10.1371/journal.pone.0030483. Epub 2012 Feb 23. PLoS One. 2012. PMID: 22383964 Free PMC article.
-
Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method.BMC Bioinformatics. 2007 Jul 4;8:238. doi: 10.1186/1471-2105-8-238. BMC Bioinformatics. 2007. PMID: 17608956 Free PMC article.
-
NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ.Immunogenetics. 2013 Oct;65(10):711-24. doi: 10.1007/s00251-013-0720-y. Epub 2013 Jul 31. Immunogenetics. 2013. PMID: 23900783 Free PMC article.
-
Based on HLA-DR beta1* allele binding specificities, striking differences in distance and TCR Contacting Residue Orientation can be observed in modified protection-inducing malarial synthetic peptides.Curr Med Chem. 2005;12(24):2849-65. doi: 10.2174/092986705774454733. Curr Med Chem. 2005. PMID: 16305475 Review.
-
MHC class II epitope predictive algorithms.Immunology. 2010 Jul;130(3):319-28. doi: 10.1111/j.1365-2567.2010.03268.x. Epub 2010 Apr 12. Immunology. 2010. PMID: 20408898 Free PMC article. Review.
Cited by
-
Leveraging Artificial Intelligence to Expedite Antibody Design and Enhance Antibody-Antigen Interactions.Bioengineering (Basel). 2024 Feb 15;11(2):185. doi: 10.3390/bioengineering11020185. Bioengineering (Basel). 2024. PMID: 38391671 Free PMC article. Review.
-
Selection of vaccine-candidate peptides from Mycobacterium avium subsp. paratuberculosis by in silico prediction, in vitro T-cell line proliferation, and in vivo immunogenicity.Front Immunol. 2024 Jan 30;15:1297955. doi: 10.3389/fimmu.2024.1297955. eCollection 2024. Front Immunol. 2024. PMID: 38352876 Free PMC article.
-
Structure-aware deep model for MHC-II peptide binding affinity prediction.BMC Genomics. 2024 Jan 30;25(1):127. doi: 10.1186/s12864-023-09900-6. BMC Genomics. 2024. PMID: 38291350 Free PMC article.
-
DeepHLAPred: a deep learning-based method for non-classical HLA binder prediction.BMC Genomics. 2023 Nov 23;24(1):706. doi: 10.1186/s12864-023-09796-2. BMC Genomics. 2023. PMID: 37993812 Free PMC article.
-
Immunoinformatics study to explore dengue (DENV-1) proteome to design multi-epitope vaccine construct by using CD4+ epitopes.J Genet Eng Biotechnol. 2023 Nov 21;21(1):128. doi: 10.1186/s43141-023-00592-9. J Genet Eng Biotechnol. 2023. PMID: 37987878 Free PMC article.
References
-
- Castellino F, Zhong G, Germain RN. Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture. Hum Immunol. 1997;54:159–169. - PubMed
-
- Sette A, Peters B. Immune epitope mapping in the post-genomic era: lessons for vaccine development. Curr Opin Immunol. 2007;19:106–110. - PubMed
-
- Lauemoller SL, Kesmir C, Corbet SL, Fomsgaard A, Holm A, et al. Identifying cytotoxic T cell epitopes from genomic and proteomic information: “The human MHC project.”. Rev Immunogenet. 2000;2:477–491. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
